Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 20,600 shares, a decline of 16.9% from the January 15th total of 24,800 shares. Based on an average daily volume of 41,200 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.3% of the shares of the stock are sold short.

Lisata Therapeutics Stock Performance

Shares of LSTA opened at $2.51 on Friday. Lisata Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $4.20. The firm has a 50 day moving average price of $3.00 and a 200-day moving average price of $2.96.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.16. During the same quarter in the prior year, the business earned ($0.65) earnings per share. Equities analysts expect that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 45.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,226 shares of the company’s stock after purchasing an additional 7,886 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.30% of Lisata Therapeutics worth $75,000 at the end of the most recent reporting period. 8.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.